06.08.2015 • NewsDede WillamsPfizerdrugs

EU Approves Pfizer-Hospira Deal With Strings

European regulatory authorities have approved the $15.2 billion takeover of injectable drug and infusion device maker Hospira by US drugmaker Pfizer, subject to certain conditions.

The Commission gave its blessing after Pfizer agreed to sell rights to some sterile injection drugs in the European Economic Area (EEA), including an experimental biosimilar version of the immune disorder drug infliximab (Remicade) and several additional products, including chemotherapy drugs.

On the divestment list in addition to Remicade are the antifungal drug voriconazole throughout the EEA and the chemotherapy drugs carboplatin, cytarabine, epirubicin, and irinotecan, along with and the antibiotic vancomycin in a few countries.

Brussels said it was concerned the deal would have led to overlaps in the Pfizer portfolio for sterile injectables and biosimilars and would have reduced competition for certain drugs in  some countries or in the European Economic Area as a whole, In particular, it posed the threat of price rises as well as the discontinuation of the development of infliximab.

"This is not just about keeping prices low for patients and healthcare services," said Competition Commissioner Margrethe Vestager. "We have also made sure," she added, that the merger of Pfizer / Hospira does not stand in the way of the research and development of medication that could have huge benefits for society ".

New York –based Pfizer, world’s second-largest pharmaceutical producer in terms of revenue, agreed to buy Hospira of Illinois in February of this year to strengthen its position in the growing market for biosimilars. Pfizer expects to complete the acquisition before the end of 2015.

Interview

Innovation at the Intersection of AI
Digital Potential in Key Business Areas

Innovation at the Intersection of AI

Stefan Guertzgen spoke with John Banovetz, Chief Technology Officer at 3M, about the role of digital transformation in achieving the company's objectives.

Free Virtual Event

ProteiNext 2025

ProteiNext 2025

ProteiNext is an annual symposium that offers a platform for sharing insights on protein analysis

most read

Photo
08.11.2024 • News

Future Prospects in Green Chemistry

The Discourse on Green Chemistry Interactive Pitch Competition, held on November 5, 2024, at Wiley's Berlin office as part of Berlin Science Week, showcased a range of innovative projects aimed at addressing critical environmental challenges.

Photo
27.03.2025 • News

J&J to Invest $55 Billion in US Operations

US healthcare giant Johnson & Johnson (J&J) has unveiled plans to invest over $55 billion in the US over the next four years. This significant investment marks a 25% increase compared to the previous four years, the company said.